✨ Medicines Consent Notices




NEW ZEALAND GAZETTE, No. 86 β€” 29 SEPTEMBER 2016

Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:

Quetiapine multichem
Quetiapine fumarate 115.13mg equivalent to quetiapine 100mg
Film coated tablet
Multichem NZ Limited
Cipla Limited, Verna, India

Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:

Quetiapine multichem
Quetiapine fumarate 172.695mg equivalent to quetiapine 150mg
Film coated tablet
Multichem NZ Limited
Cipla Limited, Verna, India

Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:

Quetiapine multichem
Quetiapine fumarate 230.26mg equivalent to quetiapine 200mg
Film coated tablet
Multichem NZ Limited
Cipla Limited, Verna, India

Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:

Quetiapine multichem
Quetiapine fumarate 345.39mg equivalent to quetiapine 300mg
Film coated tablet
Multichem NZ Limited
Cipla Limited, Verna, India

Dated this 22nd day of September 2016.

CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

2016-go5486

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:

Schedule

Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturers:

Slow Lopresor
Metoprolol tartrate 200mg
Modified release tablet
Novartis New Zealand Limited
Novartis Farma SpA, Torre Annunziata, Italy
Novartis Saglik ve Gida Urunlei Sanayi ve Ticaret AS, Istanbul, Turkey

Dated this 22nd day of September 2016.

CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

2016-go5487

Renewal of Provisional Consent to the Distribution of a Medicine

Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:

Schedule

Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:

Alcaine
Proxymetacaine hydrochloride 5mg/mL
Eye drops, solution
Pharmaco (NZ) Limited
SA Alcon Couvreur NV, Puurs, Belgium

Note: This renewed consent is valid for two years from 2 October 2016.

38



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2016, No 86





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines (continued from previous page)

πŸ₯ Health & Social Welfare
22 September 2016
Medicines Act, New Medicines, Quetiapine, Consent
  • CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health

πŸ₯ Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
22 September 2016
Medicines Act, New Medicine, Metoprolol tartrate, Consent
  • CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health

πŸ₯ Renewal of Provisional Consent to the Distribution of a Medicine

πŸ₯ Health & Social Welfare
22 September 2016
Medicines Act, Provisional Consent, Proxymetacaine hydrochloride, Renewal
  • CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health